WANY
HAE icon

Wealthspire Advisors (New York)’s Haemonetics HAE Stock Holding History

Wealthspire Advisors (New York)’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-263
Closed -$12.8K – 1817
2025
Q3 		$12.8K Buy
+263
New +$16.3K ﹤0.01% 1894

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wealthspire Advisors (New York)'s HAE Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 263 shares — an estimated $12.8K sold.

Wealthspire Advisors (New York) first reported a position in HAE in Q3 2025 and held it in 1 quarter. The position peaked at $12.8K in Q3 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 263 Haemonetics shares in Q4 2025, an estimated $12.8K.
  • Wealthspire Advisors (New York) first reported a position in Haemonetics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Haemonetics position peaked at $12.8K in Q3 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.